Figure 4 Cox regression analysis of serum Tim-3 in HCC patients receiving TACE treatment. (A) Univariate Cox regression analysis for progression, in the training set, when the patients were stratified into 2 subgroups according to serum Tim-3 levels. (B) Univariate Cox regression analysis for overall survival, in the training set, when the patients were stratified into 2 subgroups according to serum Tim-3 levels. (C) Univariate Cox regression analysis for progression, in the validation set, when the patients were stratified into 2 subgroups according to serum Tim-3 levels. (D) Univariate Cox regression analysis for overall survival, in the validation set, when the patients were stratified into 2 subgroups according to serum Tim-3 levels. (E) Multivariate Cox regression analysis for progression, in the training set, when the patients were stratified into 2 subgroups according to serum Tim-3 levels. (F) Multivariate Cox regression analysis for overall survival, in the training set, when the patients were stratified into 2 subgroups according to serum Tim-3 levels. (G) Multivariate Cox regression analysis for progression, in the validation set, when the patients were stratified into 2 subgroups according to serum Tim-3 levels. (H) Multivariate Cox regression analysis for overall survival, in the validation set, when the patients were stratified into 2 subgroups according to serum Tim-3 levels. HCC – hepatocellular carcinoma; TACE – transcatheter arterial chemoembolization; Tim-3 – T cell immunoglobulin and mucin domain 3.